Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-6615 in symptomatic hypertrophic cardiomyopathy
2013-004429-97Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing GS-6615 with Placebo (2 arms). Primary endpoint: Change in Peak VO2 from baseline to Week 24. Started Nov 2014; status: terminated.
02
Drugs
eleclazine
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2013-004429-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004429-97.